To explore the clinical effect of hydrotubation combined with bromocriptine in treatment of infertility patients caused by hyperprolactinemia (HPRL) and complicated with tubal obstruction, and its effect on serum luteinizing hormone (LH) and anti-acrosin antibody (AcrAb).

A total of 102 patients with infertility caused by HPRL and complicated with tubal obstruction in Mianyang Central Hospital from June 2017 to June 2018 were selected as research subjects. They were randomly divided into observation group (n=51) and control group (n=51) by random digits table method. Patients in observation group were treated with hydrotubation combined with bromocriptine. And patients in control group were treated with hydrotubation. The levels of serum LH and AcrAb were detected by chemiluminescence method and enzyme-linked immunosorbent assay. After treatment, the two groups were followed up for 1 year to observe their pregnancy situation. Duration of hydrotubation, intraoperative blood loss and postoperative ambulation time, levels of serum LH and AcrAb, and the time from the end of treatment to pregnancy between two groups were compared by independent-samples t test. Total effective rates of tubal obstruction, adverse reaction and pregnancy between two groups were compared by chi-square test. This study was approved by the Ethics Committee of Mianyang Central Hospital (Approval No. S-2018-022), and clinical research informed consent was signed with each patient. There were no significant differences in age, duration of infertility and other general clinical data between two groups (P>0.05).

①There were no significant differences in duration of hydrotubation, intraoperative blood loss and postoperative ambulation time between two groups (P>0.05). ②The total effective rate of tubal obstruction in observation group was 82.3% (42/51), which was significantly higher than that of control group 64.7% (33/51), and the difference was statistically significant (χ²=4.080, P=0.043). ③Comparisons between two groups: after treatment, the serum LH level of observation group was (5.59±0.58) IU/L, which was significantly higher than those of control group (5.36±0.57) IU/L, and the serum AcrAb levels were (12.2±2.5) U/L, which was significantly lower than those of control group (14.2±2.9) U/L, and both the differences were statistically significant (t=2.002, P=0.048; t=3.743, P<0.001). Intra-group comparisons: after treatment, serum LH levels in two groups were significantly higher than those before treatment within group, while serum AcrAb levels were significantly lower than those before treatment within group, and all the differences were statistically significant (P<0.05). ④During 1-year follow-up after treatment, the pregnancy rate in observation group was 70.6% (36/51), which was significantly higher than that in control group 51.0% (26/51), the time from the end of treatment to pregnancy was (4.0±1.0) months, which was significantly shorter than that of control group (5.3±1.1) months, and both the differences were statistically significant (χ²=4.110, P=0.043; t=6.053, P<0.001). ⑤There was no significant difference in rate of adverse reaction related with treatment between two groups (P>0.05).

Hydrotubation combined with bromocriptine in treatment of patients with infertility caused by HPRL complicated with tubal obstruction has a good effect, and the pregnancy rate is increased. It can effectively improve serum levels of LH and AcrAb, but does not increase the rate of adverse reactions. Due to the relatively small sample size included in this study, the therapeutic effect of this regimen remains to be further confirmed by large-sample size, multi-center and randomized controlled trials.